Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytokinetics focuses on aficamten development post-FDA action, eyes international growth

Cytokinetics is navigating challenges post-CRL for omecamtiv mecarbil while focusing on aficamten's development.
Financially, the company is balancing increased expenses with revenue growth and strategic investments in R&D.
Key milestones for 2023 include FDA meetings for omecamtiv mecarbil and data expectations for aficamten.
The company's emphasis on aficamten's differentiation and clinical progress signals a strategic shift in focus.

Cytokinetics shifts focus to cardiovascular pipeline, optimistic outlook ahead

Cytokinetics focusing on cardiovascular pipeline progress, redirecting resources.
Optimistic outlook for aficamten and other cardiovascular drug candidates.
Financially stable with cash reserves and strategic cost-saving measures.

Cytokinetics reports strong Q2 progress, eyes market expansion opportunities

Cytokinetics made significant strides in Q2 2023, advancing key studies and reducing operating spending to enhance financial stability.
Positive data and progress in cardiovascular therapies showcase the company's potential in treating HCM and positioning in the market.
While facing challenges in stock performance and data disclosures, Cytokinetics remains poised for growth with opportunities in novel therapies and market expansion.

Cytokinetics excels in Q3 with aficamten progress and commercial readiness

Cytokinetics demonstrated strong operational and financial performance in Q3 2023, with a focus on advancing the aficamten program and preparing for potential commercialization.
While facing challenges related to data interpretation complexities and real-world beta blocker usage, the company remains well-positioned with compelling clinical aspects of aficamten.
Opportunities lie in potential partnerships for capital access, broad market potential across regions, and upcoming data disclosures driving market differentiation.

Cytokinetics excels with positive aficamten trial results and strategic focus

Cytokinetics' Q4 2023 marked a significant milestone with positive aficamten trial results, strong financial standing, and strategic focus on regulatory advancements and market expansion.
The company's strengths lie in aficamten's efficacy, financial stability, and potential for differentiated labeling, while challenges include adoption transitions and data analysis complexities.
Opportunities abound in accelerating NDA submission, expanding patient reach, engaging with payors, and leveraging data insights for enhanced patient outcomes and market positioning.
Overall, Cytokinetics is poised for growth and impact in 2024, with a clear roadmap for success in advancing aficamten and maximizing its therapeutic potential in the HCM market.

Cytokinetics advances aficamten for HCM treatment amid financial strength

Cytokinetics is making significant strides in advancing aficamten for HCM treatment, supported by positive results and regulatory engagements.
The company's financial strength and strategic focus on commercial readiness position it well for future growth and market penetration.
Challenges lie in addressing unmet needs in pediatric HCM, enrollment completion for ongoing trials, and establishing treatment credibility.
Opportunities exist in expanding diagnosis potential, developing competitive treatment options, and enhancing regulatory alignment for global market access.

Cytokinetics advances obstructive HCM treatment with strong financials and strategic focus

Cytokinetics is poised for growth with FDA submission for aficamten and strong financial position.
Strategic focus on commercial preparations and clinical trials signals a commitment to future success.
Challenges in market competition and education require targeted efforts for successful product launch.
Emphasis on patient-centric approach and category expansion positions the company for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time.

Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach

Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program

New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024.

Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to Camzyos, implying that it could become a blockbuster treatment in HCM. CYTK's M&A appeal surged post-data, despite a dip after Novartis cooled acquisition talks; the current market cap suggests upside potential.

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Novartis

Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS).  Shares of the biopharmaceutical company have more than doubled since the end of October on speculation of a deal, and on Wednesday the stock closed at $101.63 on speculation that a deal would go through.

Cytokinetics stock plunges as Novartis retreats from merger talks

Novartis has backed away from its pursuit of Cytokinetics , the Wall Street Journal reported on Thursday, citing sources.

Novartis drops pursuit of Cytokinetics - WSJ

Novartis has backed away from its pursuit of Cytokinetics.

Novartis Pursuit of Cytokinetics Cools

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

Cytokinetics Inc (NASDAQ: CYTK) popped another 15% on Monday following a report that Novartis AG (SWX: NOVN) is now in advanced talks to acquire the biopharmaceutical firm.

Novartis in advanced talks to buy Cytokinetics

Novartis is closing in on a takeover of Cytokinetics, the Wall Street Journal reported Monday, leading CYTK stock to soar in afternoon action.

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal

Novartis NOVN, +0.43% is close to acquiring Cytokinetics Inc. CYTK, +15.04% and its promising heart drug, according to a Wall Street Journal report Monday. A deal for South San Francisco-based Cytokinetics, which has a market value of about $9 billion, could be finalized as soon as this week, according to people familiar with the situation, the Journal reported.

Novartis, Cytokinetics near merger: report

Swiss drugmaker Novartis is close to acquiring Cytokinetics and the deal could be finalized as soon as this week, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Novartis in advanced talks to buy Cytokinetics- WSJ

Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug.

Novartis in Advanced Talks to Buy Cytokinetics

BridgeBio Pharma Inc

With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumored to be receiving takeover interest from larger peers.

2 Biotechs That Could Get Bought Out in 2024

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Shares of Cytokinetics (CYTK) blasted off Wednesday after the firm announced positive results in a study of its experimental heart treatment.

Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug

Demonstrating the positive side of the occasional feast-or-famine nature of publicly traded biotechnology firms, Cytokinetics (NASDAQ: CYTK ) soared Wednesday following the disclosure of its positive late-stage clinical trial data. A specialist in the field of muscle activators and inhibitors, Cytokinetics' heart failure drug met its main target.

Why Is Cytokinetics (CYTK) Stock Up 70% Today?

Cytokinetics' share price surged after announcing positive results from the phase 3 SEQUOIA-HCM trial of aficamten. Aficamten showed better efficacy, safety, and convenience compared to Camzyos, positioning it as a potential best-in-class drug. The results warrant an increased valuation range and further increase the probability of the company being acquired.

Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)

Shares of Cytokinetics Inc. CYTK, +2.49% rocketed 41.1% toward a record one-day gain in premarket trading, after the cardiovascular biopharmaceutical company announced positive results from a Phase 3 trial of aficamten, a treatment for hypertrophic cardiomyopathy (HCM). The stock was on track to open at the highest price seen on a closing basis since Dec. 30, 2004.

Cytokinetics stock rockets toward a 19-year high after positive trial data on heart disease treatment

Drug developer Cytokinetics said on Wednesday its experimental drug aficamten, to treat a type of chronic heart disease, had met the main goal of a keenly awaited late-stage study.

Cytokinetics' heart disease drug meets main goal in study

Cytokinetics said on Wednesday that its experimental heart disease drug met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival treatment from Bristol Myers Squibb.

News for Cytokinetics Stock (CYTK)